China Wraps Up Round 2 of Centralized Drug

PurchaseCountry: CHINA | Region: ASIA & SOUTH PACIFIC | Type: Regulation | Keywords: #bmi #drugpurchase #nhsa #pricereductions #shanghaidrugpurchasenetwork #tender

PRICENTRIC BRIEF:

  • The Shanghai Drug Purchase Network, the National Health Security Administration’s (NHSA) executive for Round 2 of the National Level Centralized Drug Purchase Program, announced that Round 2 includes the purchase of 33 drugs regarding 50 specifications
  • According to Chinese media, the average price reduction by prevailing suppliers in Round 2 is between 60% and 80%, with the highest single price reduction at 93% from Hunan Jiudian Pharma for levocetirizine oral regular release dosage forms
  • Domestic manufacturers that participated in the bidding and won big include Qilu Pharma, Kelun Pharma, Yangzijang Pharma, Shijiazhuang Pharma, and Hengrui Medicines, and 26 foreign drugmakers participated, including Bayer, GSK, Pfizer, Sanofi, and Servier

 

THE DETAILS

BEIJING, China – The Shanghai Drug Purchase Network, the National Health Security Administration’s (NHSA) executive for Round 2 of the National Level Centralized Drug Purchase Program, announced that Round 2 includes the purchase of 33 drugs regarding 50 specifications.

The products are mostly for diabetes, hypertension, oncology, and rare diseases, and a total of 122 pharmaceutical companies partook in the bidding.

Three drugs not reimbursed by the basic medical insurance (BMI) scheme were included in Round 2: Ambrisentan tablets, tadalafil tablets, and paclitaxel for injection (albumin bound).

According to Chinese media, the average price reduction by prevailing suppliers in Round 2 is between 60% and 80%, with the highest single price reduction at 93% from Hunan Jiudian Pharma for levocetirizine oral regular release dosage forms.

The total purchase value for Round 2 is anticipated to exceed CNY 8.7 billion. For 15 of the 33 drug products under Round 2, the purchase value is expected to exceed CNY 100 million. The purchase value of Acarbose is the highest at CNY 2.9 billion.

Domestic manufacturers that participated in the bidding and won big include Qilu Pharma, Kelun Pharma, Yangzijang Pharma, Shijiazhuang Pharma, and Hengrui Medicines, and 26 foreign drugmakers participated, including Bayer, GSK, Pfizer, Sanofi, and Servier.

 

Learn more about Pricentric One and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.